<DOC>
	<DOCNO>NCT01061658</DOCNO>
	<brief_summary>A double blind placebo control Phase I/II study evaluate safety immunogenicity Live Attenuated Tetravalent ( G1-G4 ) Bovine-Human Reassortant Rotavirus Vaccine [ BRV-TV ] Indian infant . The study would carry 90 healthy infant . Three dos rotavirus vaccine placebo would administer orally infant 6-8 , 10-12 14-16 week age . The rotavirus vaccine would administer one two plan virus concentration ( 10e5.5 10e6.25 FFU constituent serotype per 0.5 ml ) . Each administration vaccine/placebo would precede oral administration 2.0 mL antacid .</brief_summary>
	<brief_title>Safety Immunogenicity Study Tetravalent Rotavirus Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant 68 week age time enrollment either sex ; Born gestational period 3642 week birth weight ≥2 kg ; Father , mother legally acceptable representative ( guardian ) properly inform study sign informed consent form ( ICF ) . In case father , mother legally acceptable representative ( guardian ) unable read write , ICF explain presence study independent witness witness sign ICF ; Parent guardian available entire period study reachable study staff postvaccination followup . History congenital abdominal disorder , intussusception , abdominal surgery ; Known suspect impairment immunological function ; Known hypersensitivity component rotavirus vaccine ; Prior receipt rotavirus vaccine ; Fever , axillary temperature ≥38.1oC ( ≥100.5oF ) ; measure study staff . History known rotavirus disease , chronic diarrhea , failure thrive ; Baseline level ALT AST &gt; 2.5 time upper limit normal ; Clinical evidence active gastrointestinal illness ( infant GERD participate study long condition well control without medication ) ; Receipt IM , oral , IV corticosteroid treatment past 30 day ( infant inhale steroid may permit participate study ) ; Infants reside household immunocompromised person ( e.g. , individual congenital immunodeficiency , HIV infection , leukemia , lymphoma , Hodgkin 's disease , multiple myeloma , generalized malignancy , chronic renal failure , nephrotic syndrome , organ bone marrow transplantation , receive immunosuppressive chemotherapy include longterm systemic corticosteroid ) ; Infants suspect HIV , HBV HCV positive available clinical history born mother know HIV , HBV HCV positive . Prior receipt blood transfusion blood product , include immunoglobulin ; Any infant adequately follow safety home visit ; Any condition , opinion investigator , might interfere evaluation study objective . Parent/s guardian subject unable maintain diary card</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>